Cargando…

Systems biology of industrial oxytetracycline production in Streptomyces rimosus: the secrets of a mutagenized hyperproducer

BACKGROUND: Oxytetracycline which is derived from Streptomyces rimosus, inhibits a wide range of bacteria and is industrially important. The underlying biosynthetic processes are complex and hinder rational engineering, so industrial manufacturing currently relies on classical mutants for production...

Descripción completa

Detalles Bibliográficos
Autores principales: Beganovic, Selma, Rückert-Reed, Christian, Sucipto, Hilda, Shu, Wei, Gläser, Lars, Patschkowski, Thomas, Struck, Ben, Kalinowski, Jörn, Luzhetskyy, Andriy, Wittmann, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612213/
https://www.ncbi.nlm.nih.gov/pubmed/37898787
http://dx.doi.org/10.1186/s12934-023-02215-x
_version_ 1785128652440076288
author Beganovic, Selma
Rückert-Reed, Christian
Sucipto, Hilda
Shu, Wei
Gläser, Lars
Patschkowski, Thomas
Struck, Ben
Kalinowski, Jörn
Luzhetskyy, Andriy
Wittmann, Christoph
author_facet Beganovic, Selma
Rückert-Reed, Christian
Sucipto, Hilda
Shu, Wei
Gläser, Lars
Patschkowski, Thomas
Struck, Ben
Kalinowski, Jörn
Luzhetskyy, Andriy
Wittmann, Christoph
author_sort Beganovic, Selma
collection PubMed
description BACKGROUND: Oxytetracycline which is derived from Streptomyces rimosus, inhibits a wide range of bacteria and is industrially important. The underlying biosynthetic processes are complex and hinder rational engineering, so industrial manufacturing currently relies on classical mutants for production. While the biochemistry underlying oxytetracycline synthesis is known to involve polyketide synthase, hyperproducing strains of S. rimosus have not been extensively studied, limiting our knowledge on fundamental mechanisms that drive production. RESULTS: In this study, a multiomics analysis of S. rimosus is performed and wild-type and hyperproducing strains are compared. Insights into the metabolic and regulatory networks driving oxytetracycline formation were obtained. The overproducer exhibited increased acetyl-CoA and malonyl CoA supply, upregulated oxytetracycline biosynthesis, reduced competing byproduct formation, and streamlined morphology. These features were used to synthesize bhimamycin, an antibiotic, and a novel microbial chassis strain was created. A cluster deletion derivative showed enhanced bhimamycin production. CONCLUSIONS: This study suggests that the precursor supply should be globally increased to further increase the expression of the oxytetracycline cluster while maintaining the natural cluster sequence. The mutagenized hyperproducer S. rimosus HP126 exhibited numerous mutations, including large genomic rearrangements, due to natural genetic instability, and single nucleotide changes. More complex mutations were found than those typically observed in mutagenized bacteria, impacting gene expression, and complicating rational engineering. Overall, the approach revealed key traits influencing oxytetracycline production in S. rimosus, suggesting that similar studies for other antibiotics could uncover general mechanisms to improve production. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-023-02215-x.
format Online
Article
Text
id pubmed-10612213
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106122132023-10-29 Systems biology of industrial oxytetracycline production in Streptomyces rimosus: the secrets of a mutagenized hyperproducer Beganovic, Selma Rückert-Reed, Christian Sucipto, Hilda Shu, Wei Gläser, Lars Patschkowski, Thomas Struck, Ben Kalinowski, Jörn Luzhetskyy, Andriy Wittmann, Christoph Microb Cell Fact Research BACKGROUND: Oxytetracycline which is derived from Streptomyces rimosus, inhibits a wide range of bacteria and is industrially important. The underlying biosynthetic processes are complex and hinder rational engineering, so industrial manufacturing currently relies on classical mutants for production. While the biochemistry underlying oxytetracycline synthesis is known to involve polyketide synthase, hyperproducing strains of S. rimosus have not been extensively studied, limiting our knowledge on fundamental mechanisms that drive production. RESULTS: In this study, a multiomics analysis of S. rimosus is performed and wild-type and hyperproducing strains are compared. Insights into the metabolic and regulatory networks driving oxytetracycline formation were obtained. The overproducer exhibited increased acetyl-CoA and malonyl CoA supply, upregulated oxytetracycline biosynthesis, reduced competing byproduct formation, and streamlined morphology. These features were used to synthesize bhimamycin, an antibiotic, and a novel microbial chassis strain was created. A cluster deletion derivative showed enhanced bhimamycin production. CONCLUSIONS: This study suggests that the precursor supply should be globally increased to further increase the expression of the oxytetracycline cluster while maintaining the natural cluster sequence. The mutagenized hyperproducer S. rimosus HP126 exhibited numerous mutations, including large genomic rearrangements, due to natural genetic instability, and single nucleotide changes. More complex mutations were found than those typically observed in mutagenized bacteria, impacting gene expression, and complicating rational engineering. Overall, the approach revealed key traits influencing oxytetracycline production in S. rimosus, suggesting that similar studies for other antibiotics could uncover general mechanisms to improve production. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-023-02215-x. BioMed Central 2023-10-28 /pmc/articles/PMC10612213/ /pubmed/37898787 http://dx.doi.org/10.1186/s12934-023-02215-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Beganovic, Selma
Rückert-Reed, Christian
Sucipto, Hilda
Shu, Wei
Gläser, Lars
Patschkowski, Thomas
Struck, Ben
Kalinowski, Jörn
Luzhetskyy, Andriy
Wittmann, Christoph
Systems biology of industrial oxytetracycline production in Streptomyces rimosus: the secrets of a mutagenized hyperproducer
title Systems biology of industrial oxytetracycline production in Streptomyces rimosus: the secrets of a mutagenized hyperproducer
title_full Systems biology of industrial oxytetracycline production in Streptomyces rimosus: the secrets of a mutagenized hyperproducer
title_fullStr Systems biology of industrial oxytetracycline production in Streptomyces rimosus: the secrets of a mutagenized hyperproducer
title_full_unstemmed Systems biology of industrial oxytetracycline production in Streptomyces rimosus: the secrets of a mutagenized hyperproducer
title_short Systems biology of industrial oxytetracycline production in Streptomyces rimosus: the secrets of a mutagenized hyperproducer
title_sort systems biology of industrial oxytetracycline production in streptomyces rimosus: the secrets of a mutagenized hyperproducer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612213/
https://www.ncbi.nlm.nih.gov/pubmed/37898787
http://dx.doi.org/10.1186/s12934-023-02215-x
work_keys_str_mv AT beganovicselma systemsbiologyofindustrialoxytetracyclineproductioninstreptomycesrimosusthesecretsofamutagenizedhyperproducer
AT ruckertreedchristian systemsbiologyofindustrialoxytetracyclineproductioninstreptomycesrimosusthesecretsofamutagenizedhyperproducer
AT suciptohilda systemsbiologyofindustrialoxytetracyclineproductioninstreptomycesrimosusthesecretsofamutagenizedhyperproducer
AT shuwei systemsbiologyofindustrialoxytetracyclineproductioninstreptomycesrimosusthesecretsofamutagenizedhyperproducer
AT glaserlars systemsbiologyofindustrialoxytetracyclineproductioninstreptomycesrimosusthesecretsofamutagenizedhyperproducer
AT patschkowskithomas systemsbiologyofindustrialoxytetracyclineproductioninstreptomycesrimosusthesecretsofamutagenizedhyperproducer
AT struckben systemsbiologyofindustrialoxytetracyclineproductioninstreptomycesrimosusthesecretsofamutagenizedhyperproducer
AT kalinowskijorn systemsbiologyofindustrialoxytetracyclineproductioninstreptomycesrimosusthesecretsofamutagenizedhyperproducer
AT luzhetskyyandriy systemsbiologyofindustrialoxytetracyclineproductioninstreptomycesrimosusthesecretsofamutagenizedhyperproducer
AT wittmannchristoph systemsbiologyofindustrialoxytetracyclineproductioninstreptomycesrimosusthesecretsofamutagenizedhyperproducer